AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Recurrent Plasma Cell Myeloma

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 NCT07623798Phase 31 site๐Ÿ“ Shanghai Innovent Biologics (Suzhou) Co. Ltd. ยท Tests: Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection), IBI3003, Selinexor Tabโ€ฆ A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT05519085Phase 3266 sites๐Ÿ“ Los Alamitos๐Ÿ“ San Diego๐Ÿ“ West Hollywood Celgene ยท Tests: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma NCT05530421Phase 23 sites๐Ÿ“ Coral Gables๐Ÿ“ Deerfield Beach๐Ÿ“ Miami University of Miami ยท Tests: Selinexor, Venetoclax, Dexamethasone A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) NCT07771803EARLY Phase 11 site๐Ÿ“ Camden Roger Strair ยท Tests: Soursop tea Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma NCT07657312Phase 21 site๐Ÿ“ Columbus Naresh Bumma ยท Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma NCT04508790Phase 28 sites๐Ÿ“ Duarte๐Ÿ“ Huntington Beach๐Ÿ“ Lancaster City of Hope Medical Center ยท Tests: Dexamethasone, Leflunomide, Pomalidomide Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis NCT06971380Phase 21 site๐Ÿ“ Jerusalem Polina Stepensky ยท Tests: HBI0101 CART Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma NCT05847569Phase 21 site๐Ÿ“ Jacksonville Mayo Clinic ยท Tests: Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma NCT07681596Phase 1, Phase 212 sites๐Ÿ“ Duarte๐Ÿ“ Denver๐Ÿ“ Tampa AstraZeneca ยท Tests: AZD4045, Daratumumab, Aldesleukin A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) NCT05927571Phase 114 sites๐Ÿ“ Camperdown๐Ÿ“ Waratah๐Ÿ“ Adelaide Genentech, Inc. ยท Tests: Cevostamab, Elranatamab, Tocilizumab Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+ NCT06874530n/a1 site๐Ÿ“ Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma NCT07579234Phase 31 site๐Ÿ“ Tianjing Shandong New Time Pharmaceutical Co., LTD ยท Tests: F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) Selinexor and Backbone Treatments of Multiple Myeloma Patients NCT02343042Phase 1, Phase 225 sites๐Ÿ“ Gilbert๐Ÿ“ Los Angeles๐Ÿ“ Denver Karyopharm Therapeutics Inc ยท Tests: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease NCT06627751Phase 21 site๐Ÿ“ Buffalo Roswell Park Cancer Institute ยท Tests: Mezigdomide, Carfilzomib, Dexamethasone, Echocardiography, Positron Emission Tomography Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma NCT06940297Phase 21 site๐Ÿ“ Rochester Mayo Clinic ยท Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Ciltacabtagene Autoleucel A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence NCT06767254n/a4 sites๐Ÿ“ Meldola๐Ÿ“ Bologna๐Ÿ“ Cagliari IRCCS Azienda Ospedaliero-Universitaria di Bologna In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma NCT07715630Phase 11 site๐Ÿ“ Kunming Chongqing Precision Biotech Co., Ltd ยท Tests: Invivo CAR-T A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma NCT06574568Phase 112 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Foshan Excyte Biopharma Ltd ยท Tests: YKST02 Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment NCT07463807Phase 1, Phase 21 site๐Ÿ“ Duarte National Cancer Institute (NCI) ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis NCT05652335Phase 129 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ San Francisco Janssen Research & Development, LLC ยท Tests: JNJ-79635322 Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma NCT06581640Phase 21 site๐Ÿ“ Xiamen The First Affiliated Hospital of Xiamen University ยท Tests: CAR-T treatment Human BCMA Targeted T Cells Injection๏ผˆBCMA CAR-T๏ผ‰for Subjects With R/R MM NCT05594797Phase 22 sites๐Ÿ“ Shanghai๐Ÿ“ Wenzhou Hrain Biotechnology Co., Ltd. ยท Tests: Human BCMA Targeted T Cells Injection Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects NCT07280013Phase 120 sites๐Ÿ“ Gilbert๐Ÿ“ Sacramento๐Ÿ“ Santa Monica C4 Therapeutics, Inc. ยท Tests: Cemsidomide, Elranatamab Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse NCT06827860Phase 21 site๐Ÿ“ New York Larysa Sanchez ยท Tests: Talquetamab, Daratumumab Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma NCT07725406Phase 11 site๐Ÿ“ New York Weill Medical College of Cornell University ยท Tests: Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapโ€ฆ Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma NCT05312255NA1 site๐Ÿ“ Buffalo Roswell Park Cancer Institute ยท Tests: Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol, Quality-of-Life Assessment, Questionnaire Administratโ€ฆ A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma NCT07312188Phase 21 site๐Ÿ“ Tianjin Shandong New Time Pharmaceutical Co., LTD ยท Tests: F182112+P, F182112+CD38 Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003568Phase 11 site๐Ÿ“ Shanghai Beijing GoBroad Hospital ยท Tests: Dual-targeting BCMA-GPRC5D CAR-T cell infusion
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy